Skip to main content

RT @RichardPAConway: Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year

Social Author Name
Richard Conway
Tweet Content
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K

RT @RichardPAConway: Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect se

Social Author Name
Richard Conway
Tweet Content
Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6

RT @RichardPAConway: Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2

Social Author Name
Richard Conway
Tweet Content
Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2 trials @RheumNow #ACR22 Abstr#1893 https://t.co/RrrelHDz75 https://t.co/Sf7RpjjAaN

RT @JulianSegan: Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA,

Social Author Name
Julian Segan
Tweet Content
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action? @RheumNow ABST0297 #ACR22 https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB

RT @RichardPAConway: Shanahan et al. RCT of Genicular nerve block for knee OA. It works but temporary, with loss of effe

Social Author Name
Richard Conway
Tweet Content
Shanahan et al. RCT of Genicular nerve block for knee OA. It works but temporary, with loss of effect by week 12. @RheumNow #ACR22 Abstr#1892 https://t.co/VySjBGrVeR https://t.co/JNKQeOVB6z

RT @JulianSegan: In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than ot

Social Author Name
Julian Segan
Tweet Content
In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF). Good to see more direct data rather than having to extrapolate from flu. @RheumNow ABST0913 #ACR22 https://t.co/YphKywNJfA

RT @Yuz6Yusof: Please find our Day 2 #ACR22 Daily Recap Video by @RheumNow Faculty https://t.co/f3BbKkgzRp @Janetbir

Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
Please find our Day 2 #ACR22 Daily Recap Video by @RheumNow Faculty https://t.co/f3BbKkgzRp @Janetbirdope @synovialjoints @doctorRBC @bella_mehta @AkhilSoodMD @RHEUMarampa @DrCassySims https://t.co/VZM53cUyWL

RT @RichardPAConway: Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing

Social Author Name
Richard Conway
Tweet Content
Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing CVD. @RheumNow #ACR22 Abstr#1815 https://t.co/tXwa2FrSrp https://t.co/8TKl4z7iaH

RT @RichardPAConway: Kastrati et al. Case series immune apheresis in IIM. 24 patients. Reduced CK in 21/24, 971 to 347.

Social Author Name
Richard Conway
Tweet Content
Kastrati et al. Case series immune apheresis in IIM. 24 patients. Reduced CK in 21/24, 971 to 347. Reduced steroid 25%, median 12.5mg reduction @RheumNow #ACR22 Abstr#1882 https://t.co/UUlm4xEX61 https://t.co/bS2IA9OKnH

RT @KDAO2011: "If your partner won't use protection, close the vault!" - Dr. J Patricia Dhar interviewed on sexual Heal

Social Author Name
TheDaoIndex
Tweet Content
"If your partner won't use protection, close the vault!" - Dr. J Patricia Dhar interviewed on sexual Health and STD Prevention in Lupus Patients. Contact her pdhar@med.wayne.edu if you want to collaborate or fund her studies. #ACR22 @rheumnow https://t.co/WDLq9Mhoiw
Subscribe to
×